Quince Therapeutics/$QNCX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Quince Therapeutics
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.
Ticker
$QNCX
Sector
Primary listing
Employees
38
Headquarters
Website
QNCX Metrics
BasicAdvanced
$21m
-
-$16.76
1.33
-
Price and volume
Market cap
$21m
Beta
1.33
52-week high
$1.53
52-week low
$1.12
Financial strength
Current ratio
0.53
Quick ratio
0.494
Long term debt to equity
-0.924
Total debt to equity
-51.719
Interest coverage (TTM)
-55.17%
Profitability
EBITDA (TTM)
-50.287
Effective tax rate (TTM)
-3.98%
Management effectiveness
Return on assets (TTM)
-30.31%
Return on equity (TTM)
3,016.49%
Valuation
Price to book
-0.2
Price to tangible book (TTM)
-0.07
Price to free cash flow (TTM)
-0.157
Free cash flow yield (TTM)
-636.62%
Free cash flow per share (TTM)
-8.339
Growth
Earnings per share change (TTM)
27.62%
3-year earnings per share growth (CAGR)
2.82%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Quince Therapeutics stock?
Quince Therapeutics (QNCX) has a market cap of $21M as of May 01, 2026.
What is the P/E ratio for Quince Therapeutics stock?
The price to earnings (P/E) ratio for Quince Therapeutics (QNCX) stock is 0 as of May 01, 2026.
Does Quince Therapeutics stock pay dividends?
No, Quince Therapeutics (QNCX) stock does not pay dividends to its shareholders as of May 01, 2026.
When is the next Quince Therapeutics dividend payment date?
Quince Therapeutics (QNCX) stock does not pay dividends to its shareholders.
What is the beta indicator for Quince Therapeutics?
Quince Therapeutics (QNCX) has a beta rating of 1.33. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.